Celcuity LLC
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $9.24
- Today's High:
- $9.84
- Open Price:
- $9.44
- 52W Low:
- $6.99
- 52W High:
- $14.402
- Prev. Close:
- $9.35
- Volume:
- 48426
Company Statistics
- Market Cap.:
- $237.16 million
- Book Value:
- 5.616
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.69%
- Return on Equity TTM:
- -48.03%
Company Profile
Celcuity LLC had its IPO on 2017-09-20 under the ticker symbol CELC.
The company operates in the Healthcare sector and Biotechnology industry. Celcuity LLC has a staff strength of 45 employees.
Stock update
Shares of Celcuity LLC opened at $9.44 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $9.24 - $9.84, and closed at $9.54.
This is a +2.03% increase from the previous day's closing price.
A total volume of 48,426 shares were traded at the close of the day’s session.
In the last one week, shares of Celcuity LLC have slipped by -3.15%.
Celcuity LLC's Key Ratios
Celcuity LLC has a market cap of $237.16 million, indicating a price to book ratio of 3.3317 and a price to sales ratio of 0.
In the last 12-months Celcuity LLC’s revenue was $0 with a gross profit of $0 and an EBITDA of $-44232156. The EBITDA ratio measures Celcuity LLC's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celcuity LLC’s operating margin was 0% while its return on assets stood at -22.69% with a return of equity of -48.03%.
In Q1, Celcuity LLC’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Celcuity LLC’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.77 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celcuity LLC’s profitability.
Celcuity LLC stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -3.0746. Its price to sales ratio in the trailing 12-months stood at 0.
Celcuity LLC stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $164.87 million
- Total Liabilities
- $5.81 million
- Operating Cash Flow
- $21.87 million
- Capital Expenditure
- $6987
- Dividend Payout Ratio
- 0%
Celcuity LLC ended 2024 with $164.87 million in total assets and $0 in total liabilities. Its intangible assets were valued at $164.87 million while shareholder equity stood at $123.23 million.
Celcuity LLC ended 2024 with $0 in deferred long-term liabilities, $5.81 million in other current liabilities, 21941.00 in common stock, $-108235304.00 in retained earnings and $0 in goodwill. Its cash balance stood at $33.64 million and cash and short-term investments were $157.48 million. The company’s total short-term debt was $195,876 while long-term debt stood at $35.48 million.
Celcuity LLC’s total current assets stands at $164.10 million while long-term investments were $0 and short-term investments were $123.84 million. Its net receivables were $38263.00 compared to accounts payable of $2.57 million and inventory worth $0.
In 2024, Celcuity LLC's operating cash flow was $21.87 million while its capital expenditure stood at $6987.
Comparatively, Celcuity LLC paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $9.54
- 52-Week High
- $14.402
- 52-Week Low
- $6.99
- Analyst Target Price
- $24.67
Celcuity LLC stock is currently trading at $9.54 per share. It touched a 52-week high of $14.402 and a 52-week low of $14.402. Analysts tracking the stock have a 12-month average target price of $24.67.
Its 50-day moving average was $9.85 and 200-day moving average was $10.44 The short ratio stood at 22.66 indicating a short percent outstanding of 0%.
Around 2663.3% of the company’s stock are held by insiders while 5504.6% are held by institutions.
Frequently Asked Questions About Celcuity LLC
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company’s CELsignia diagnostic platform uses a patient’s living tumor cells to identify the specific abnormal cellular process driving a patient’s cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.